The extent of weight gain and its association with clinical factors in patients undergoing radioiodine therapy for differentiated thyroid cancer remain unclear. We analyzed clinical factors related to sustained weight gain after serum thyroid-stimulating hormone (TSH) stimulation for radioiodine (I-131) therapy. Materials and Methods: The study population included 301 adult patients who underwent total thyroidectomy followed by radioiodine therapy and visited the thyroid clinic regularly. Group 1 received a single radioiodine therapy treatment, while group 2 received multiple radioiodine treatment. Data on transient weight gain, defined as weight gain that resolved (±5%) within 1 year after radioiodine therapy, were collected from medical records. Sustained weight gain was defined as body mass index after treatment (BMIpost) -BMI before treatment (BMIpre) ≥2 kg/m 2 more than 1 year following radioiodine therapy. Subjective symptoms were scored by questionnaire. Logistic regression analysis was performed using various clinical and laboratory factors to identify risk factors associated with sustained weight gain. Results: Two hundred and fifty-nine (86%) patients showed transient weight gain and 23 (8%) patients showed sustained weight gain. TSH at therapy and T4-on TSH differed significantly in all patients and in the patients in group 1 with sustained weight gain. The proportion of patients with basal BMI≥25 kg/m 2 in group 1 with sustained weight gain also differed significantly. Univariate analysis revealed that high serum levels of TSH at therapy (≥100 μIU/mL) and hypercholesterolemia were associated with sustained weight gain in group 1. Multivariate analysis showed that TSH at therapy levels ≥100 μIU/mL was associated with sustained weight gain in group 1. Of 283 patients remaining after excluding those with insufficient TSH suppression during follow-up, T4-on TSH levels were lower in the sustained weight gain group compared to those without sustained weight gain. TSH at therapy levels ≥100 μIU/mL were significantly associated with sustained weight gain in multivariate analysis. Conclusion: Most patients (86%) had transient weight gain after TSH at therapy, while 8% of patients showed sustained weight gain. Univariate and multivariate analysis revealed relatively high TSH levels (≥100 μIU/mL) to be a risk factor for patients that received a single dose of radioiodine therapy. Insufficient T4 dose was not associated with sustained weight gain.
Introduction
Radioiodine (I-131) therapy has been widely used for management of patients with well-differentiated thyroid cancer. 1, 2) Since elevated serum TSH levels enhance iodine uptake in thyroid cancer cells, serum TSH levels are typically stimulated prior to radioactive iodine therapy. Serum TSH levels can be increased simply by discontinuing thyroid hormone therapy in patients that have undergone total thyroidectomy. In these cases, high TSH stimulation is accompanied by hypothyroidism. The symptoms of hypothyroidism include increased body weight. Although recombinant TSH can be used for this pretreatment, its high cost and poor availability are obstacles to its widespread use.
The importance of sustained weight gain after two weeks withdrawal of thyroid hormone has not been well studied in patients with differentiated thyroid cancer (DTC). Some patients show severe and sustained weight gain despite a return to normal or even suppressed serum TSH levels. Reports on hypothyroidism related to weight change in postoperative DTC are scarce. Sohn et al. 3) observed that only female patients with DTC showed significant gains in weight and body mass index (BMI) during long-term follow-up after initial treatment. Patients administered recombinant TSH did not gain significant weight during follow-up. In these cases, recombinant TSH may be a treatment of choice.
In the present study, we evaluated the patterns of weight gain in patients undergoing radioiodine therapy.
TSH levels and various clinical factors were analyzed in order to elucidate their relationships with weight gain.
Materials and Methods

Patient Characteristics
Korean patients who visited Seoul National University Hospital between July 2012 and December 2012 were enrolled in this study. In order to stimulate TSH levels, levothyroxine (LT4) was discontinued for 4 weeks before radioiodine therapy. Triiodothyronine (T3) was then administered for 2 weeks; this T3 replacement was discontinued for the last two weeks before radioiodine therapy. In addition, patients were instructed to follow a low-iodine diet for the last two weeks before radioiodine therapy.
4)
Definition of Sustained Weight Gain and Transient Weight Gain
Sustained weight gain was defined as more than 2 kg/m 2 increase in BMI at the 1-year follow-up. Basal BMI (BMI pre ) was measured before serum TSH elevation.
BMI post was defined as the BMI at the 1-year followup after radioiodine therapy. Transient weight gain was defined as weight gain that resolved within 1 year after radioiodine therapy. Restored body weight was 
Anthropometrical Measurements
Weight and height were measured at our clinic, with the patients wearing light clothing without shoes. Basal body weights before elevation of TSH period for radioiodine therapy were obtained from electronic medical charts. Asian populations BMI 25 kg/m 2 was used as the cut-off value for obesity in this study, and participants were classified into two groups for analysis.
5)
TSH Measurement
Regular follow-ups were conducted every 6 months.
Serum levels of TSH were measured (μIU/mL; reference range, 0.4-4.1; BRAHMS Diagnostica, Berlin, Germany). T4-on TSH level was defined as the average of several TSH levels during the regular 6-monthly follow-ups. TSH at therapy levels were averaged in cases of patients with multiple radioiodine therapies.
Statistical Analysis
Statistical analysis was performed using a commercial statistics package (MedCalc 9.5; MedCalc Software, Belgium). Chi-squared tests were used to evaluate the correlation between subjective discomfort scores and sustained weight gain. Chi-squared and independent t-tests were used to evaluate binary and continuous parameters for sustained weight gain, respectively.
Univariate and multivariate logistic regression analyses were used to identify parameters significantly associated with sustained weight gain. Odds ratios and p values were obtained, and p values ＜0.05 were considered statistically significant. The relationships between TSH levels and sustained weight gain were tested by ROC curve. The cutoff values of stimulated and T4-on TSH were 100 and 0.9, respectively.
Results
Patient Characteristics
A significant number of patients experienced weight gain. Of 301 patients, 259 (86%) showed transient weight gain, and 23 patients (8%) showed sustained weight gain (Table 2) . In group 1, nine (11%) patients had sustained weight gain. In group 2, 14 patients (6%) had sustained weight gain.
Subjective discomfort scores are listed in Table 3 . The proportion of patients with sustained weight gain was significantly higher in the severe and extreme discomfort groups (p＜0.0001). Sustained weight gain (BMI post −BMI pre ＜2 kg/m 2 ) was frequently observed in patients with high subjective symptom scores (Fig. 1) . 
Comparisons of TSH at Therapy and T4-on TSH Levels According to the Presence of Sustained Weight Gain
The cutoff values of TSH at therapy and T4-on TSH were determined by ROC curve analysis (Fig. 2) . Of 301 patients, TSH at therapy levels differed significantly between patients with and without sustained weight gain (180.1±97.8 and 136.2±70.8, respectively; p=0.022) ( Table 4 ). The T4-on TSH levels also differed significantly between these groups (2.1±3.6 and 1.2±2.7, respectively; p=0.021) ( Fig. 3 ).
Evaluation of Factors Associated with Sustained Weight Gain
Univariate analysis revealed that TSH at therapy levels ≥100 μIU/mL and hypercholesterolemia were The TSH at therapy cutoff value overall was 87.35 μIU/mL (sensitivity 100 and specificity 27.17). (B) The TSH at therapy cutoff value in group 1 was 100 μIU/mL (sensitivity 100 and specificity 47.54). (C) The T4-on TSH cutoff value overall was 1.73 μIU/mL (sensitivity 30.43 and specificity 82.37). (D) The T4-on TSH cutoff value in group 1 was ＞0.90 μIU/mL (sensitivity 100 and specificity 27.17).
significantly associated with sustained weight gain in group 1 (Table 5 ). However, no significant factors were revealed in group 2. Meanwhile, TSH at therapy levels ≥100 μIU/mL was a significant factor in multivariate analysis (Table 6 ). The proportions of patients with sustained weight gain according to group are shown in Fig. 4 . The proportions were higher in patients with TSH at therapy levels ≥100 μIU/mL in group 1, group 2 and overall (p＜0.05).
Analysis of Patients with Insufficient TSH Suppression During Follow-up
T4-on TSH levels were higher among patients with sustained weight gain than those without sustained weight gain (Table 4) . Eighteen patients had high T4-on TSH levels (＞4.1 μIU/mL). Of the 283 patients remaining after excluding these 18 patients, the T4-on TSH levels were lower in the sustained weight gain group than those in the no sustained weight gain (Table 7) . Hypercholesterolemia was a significant factor in univariate analysis. However, TSH at therapy levels ≥100 μIU/mL was a significant factor associated with sustained weight gain ( Tables 7, 8 ) in multivariate analysis. This finding raises questions on the effects of TSH. Furthermore, insufficient T4 dose was not associated with sustained weight gain.
Discussion
In this study, a significant number of thyroid cancer patients experienced weight gain after TSH at therapy.
We found that 86% and 8% had transient and sus- tained weight gain, respectively. Relatively high TSH at therapy serum levels (≥100 μIU/mL) was a risk factor for sustained weight change among patients who received one dose of radioiodine therapy. Insufficient T4 dose was not a causative factor of sustained weight gain.
Weight gain due to hypothyroidism has been underestimated in post-operative DTC patients. Various metabolic and cardiovascular diseases such as hypertension, 6) diabetes mellitus, and cardiorenal metabolic syndrome 7) are related to obesity. 8) Moreover, weight gain has an economic impact in terms of increasing the medical and cosmetic costs.
9) The pathophysiology of weight gain in hypothyroidism is complex and unclear. It includes genetics, environment, behavior, diet, exercise, 10) and physiologic factors.
11)
It is possible for patients to develop severe problems after repeated short-term myxedema states. In general, there were no specific symptoms of complications two weeks after discontinuation of T4. However, 8% of patients in the current study experienced sustained weight gain with symptomatic discomfort. Recently, cosmetic needs for good and healthy shape have been elucidated. Therefore, assessment of clinical factors associated with sustained weight gain is important. The results of the current study exclude the possibility that high TSH (insufficient T4) was asso- 2 ) were higher in TSH at therapy levels ≥100 μIU/mL in group 1, group 2, and overall. The values for the proportions of patients in groups 1 and 2 with sustained weight gain for TSH at therapy levels above and below 100 μIU/mL were 5% and 18%, and 3% and 8%, respectively, and 3% and 10% overall.
ciated with sustained weight gain.
Previous studies have evaluated the relationship between weight gain and thyroid function. Excess weight gain is a common complication after correction of thyrotoxicosis. Patients treated for hyperthyroidism reportedly gained weight continuously for at least 6 months after attaining a euthyroid status. 12, 13) In addition, patients treated for primary hypothyroidism showed no significant weight loss and could not achieve their basal body weight. 14) Previous studies have reported different levels of weight gain in variable groups.
Overweight and obese groups showed increased weight gain compared to the normal weight group among patients treated for thyrotoxicosis, 15) while menopausal women showed the highest weight gain among euthyroid patients undergoing thyroidectomy.
16)
Similarly, individual heterogeneity caused divergent results between dyslipidemic and glycemic controls.
17)
In this study, TSH at therapy ≥100 μIU/mL in group 1 was significantly associated with sustained weight gain in both univariate and multivariate analysis. We observed more complex patterns of weight gain or loss in group 2. Patients in group 2 experienced hypothyroidism for longer periods due to frequent therapies, and showed variable levels of TSH stimulation compared to those in group 1. Although TSH at therapy levels ≥100 μIU/mL was not a significant factor in group 2, this lack of significance could be due to variable responses to TSH at therapy. Tables 7 and 
18-20)
TSHR has been identified in a number of tissues, including the brain, testes, kidney, heart, bone, thymus, lymphocytes, adipose tissue, and fibroblasts. 
23)
Differential activation of TSHR could be a mechanism that explains differences in weight gain, while modifications in TSHR activity may affect body composition. TSHR expression is upregulated during adipogenesis. 24) Higher levels of TSHR transcripts were observed in both Graves' opthalmopathy orbital fat 25) and fat undergoing differentiation due to increased cAMP in response to TSH activation. 26) Individuals with germline mutations in the TSHR gene may demonstrate differences in body composition parameters.
27)
Although the expression levels of TSHR in human adipose tissues is always less than that in thyroid tissues, differential activity of TSHR might be a key mechanism in regulating body composition. Our patients showed significant correlations between weight gain and TSH levels. Additionally, we speculate that changes in TSHR may be a mechanism that leads to sustained severe weight gain.
There are other complex mechanisms of weight gain that include both peripheral and central factors. Ghrelin-knockout mice have a normal body size and composition, which implies that this hormone has only a small effect on body weight. 28, 31) Furthermore, ghrelin levels appear to be related to insulin resistance.
32)
This study has several limitations. First, this is a retrospective study; therefore, it is possible that patients To evaluate the basic mechanism of weight gain, further biologic research on TSH and TSHR is required.
